References

Vital signs: epidemiology and recent trends in methicillin-resistant and in methicillin-susceptible Staphylococcus aureus bloodstream infections—United States

10.15585/mmwr.mm6809e1 · 2019 · External reference

Staphylococcus aureus bacteraemia mortality: a systematic review and meta-analysis

10.1016/j.cmi.2022.03.015 · 2022 · External reference

Impact of an evidence-based bundle intervention in the quality-of-care management and outcome of Staphylococcus aureus bacteremia

10.1093/cid/cit499 · 2013 · External reference

Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children

10.1093/cid/ciq146 · 2011 · External reference

Clinical failures of appropriately-treated methicillin-resistant Staphylococcus aureus infections

10.1016/j.jinf.2008.04.003 · 2008 · External reference

Executive summary: state-of-the-art review: contemporary management of Staphylococcus aureus bacteremia: controversies in clinical practice

10.1093/cid/ciad525 · 2023 · External reference

Systematic review and meta-analysis of the efficacy and safety of vancomycin combined with β-lactam antibiotics in the treatment of methicillin-resistant Staphylococcus aureus bloodstream infections

10.1016/j.jgar.2020.09.024 · 2020 · External reference

Daptomycin plus β-lactam combination therapy for methicillin-resistant Staphylococcus aureus bloodstream infections: a retrospective, comparative cohort study

10.1093/cid/ciz746 · 2020 · External reference

Daptomycin plus fosfomycin versus daptomycin alone for methicillin-resistant Staphylococcus aureus bacteremia and endocarditis: a randomized clinical trial

10.1093/cid/ciaa1081 · 2021 · External reference

Safety and effectiveness of fifth generation cephalosporins for the treatment of methicillin-resistant Staphylococcus aureus bloodstream infections: a narrative review exploring past, present, and future

10.1080/14740338.2023.2299377 · 2024 · External reference

Ceftobiprole for treatment of complicated Staphylococcus aureus bacteremia

10.1056/nejmoa2300220 · 2023 · External reference

Ceftaroline for bloodstream infections caused by methicillin-resistant Staphylococcus aureus: a multicentre retrospective cohort study

10.1016/j.cmi.2024.11.022 · 2025 · External reference

Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia

10.1128/aac.02483-18 · 2019 · External reference

Combination ceftaroline and daptomycin salvage therapy for complicated methicillin-resistant Staphylococcus aureus bacteraemia compared with standard of care

10.1016/j.ijantimicag.2021.106310 · 2021 · External reference

Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes

10.1093/jac/dku236 · 2014 · External reference

Which trial do we need? Combination therapy with daptomycin plus ceftaroline versus standard-of-care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteraemia

10.1016/j.cmi.2024.08.011 · 2025 · External reference

Good studies evaluate the disease while great studies evaluate the patient: development and application of a desirability of outcome ranking endpoint for Staphylococcus aureus bloodstream infection

10.1093/cid/ciy766 · 2019 · External reference

Unlocking the DOOR—how to design, apply, analyse, and interpret desirability of outcome ranking endpoints in infectious diseases clinical trials

10.1016/j.cmi.2023.05.003 · 2023 · External reference

Nonparametric statistical methods in medical research

10.1213/ane.0000000000005101 · 2020 · External reference

Correct calculation of confidence interval for proportion of superior comparisons between desirability of outcome ranking scores

10.1093/cid/ciac348 · 2023 · External reference

Variable selection for propensity score models

10.1093/aje/kwj149 · 2006 · External reference

Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies

10.1002/sim.6607 · 2015 · External reference

Early initiation of ceftaroline-based combination therapy for methicillin-resistant Staphylococcus aureus bacteremia

10.1186/s12941-025-00773-z · 2025 · External reference

Global differences in the management of Staphylococcus aureus bacteremia: no international standard of care

10.1093/cid/ciad363 · 2023 · External reference

Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus

10.1128/aac.48.8.2871-2875.2004 · 2004 · External reference

Clinical subphenotypes of Staphylococcus aureus bacteremia

10.1093/cid/ciae338 · 2024 · External reference

Getting to the heart of the matter-are two agents really better than one for the treatment of staphylococcal infective endocarditis?

10.1016/j.ijid.2024.02.018 · 2024 · External reference

Effect of vancomycin or daptomycin with vs without an antistaphylococcal β-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial

10.1001/jama.2020.0103 · 2020 · External reference

Understanding vancomycin nephrotoxicity augmented by β-lactams: a synthesis of endosymbiosis, proximal renal tubule mitochondrial metabolism, and β-lactam chemistry

10.1016/s1473-3099(23)00432-2 · 2024 · External reference

Risk factors for nephrotoxicity in methicillin-resistant Staphylococcus aureus bacteraemia: a post hoc analysis of the CAMERA2 trial

10.1007/s40261-022-01204-z · 2023 · External reference

Clinical outcomes with definitive treatment of methicillin-resistant Staphylococcus aureus bacteremia with retained daptomycin and ceftaroline combination therapy vs de-escalation to monotherapy with vancomycin, daptomycin, or ceftaroline

10.1093/ofid/ofab327 · 2021 · External reference

Changing characteristics of Staphylococcus aureus bacteremia: results from a 21-year, prospective, longitudinal study

10.1093/cid/ciz112 · 2019 · External reference